Pfizer Inc. (NYSE:PFE) Position Lessened by Bender Robert & Associates

Bender Robert & Associates decreased its position in Pfizer Inc. (NYSE:PFE) by 6.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,755 shares of the biopharmaceutical company’s stock after selling 555 shares during the period. Bender Robert & Associates’ holdings in Pfizer were worth $223,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in PFE. Adage Capital Partners GP L.L.C. grew its holdings in Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after acquiring an additional 1,365,295 shares during the period. LifePlan Financial LLC acquired a new position in Pfizer in the 4th quarter worth approximately $255,000. Brookstone Capital Management grew its holdings in shares of Pfizer by 88.5% during the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock valued at $14,109,000 after buying an additional 212,369 shares in the last quarter. ETF Store Inc. grew its position in Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 727 shares in the last quarter. Finally, KLCM Advisors Inc. lifted its position in Pfizer by 75.0% in the 4th quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after buying an additional 74,487 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.1 %

Shares of NYSE PFE traded down $0.03 during midday trading on Thursday, reaching $25.39. The stock had a trading volume of 35,508,535 shares, compared to its average volume of 42,480,309. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The company’s 50 day moving average price is $27.19 and its 200 day moving average price is $28.76. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.56. The firm has a market cap of $143.77 billion, a price-to-earnings ratio of 70.25, a price-to-earnings-growth ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.14 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.24 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on PFE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.